logo
Share SHARE
FONT-SIZE Plus   Neg

Arca Continental Q1 Profit Rises

Coca-Cola bottler Arca Continental, S. A. B. de C. V. (EMBVF.PK) Friday posted higher net profit for the first quarter reflecting increased revenue for the period, primarily led by a sales rise in North America.

For the quarter, the company reported net income of 1.09 billion peso, up 11.3 percent from 979 million peso last year.

Revenue for the quarter was 13.375 billion peso, up 8.3 percent from 12.35 billion peso a year back. Net sales in North America for the quarter was 9.989 billion peso, up from 9.144 billion peso last year.

Commenting on the results, Francisco Egloff, CEO of Arca Continental said, "During the first quarter of 2013 we continued to focus on satisfying our clients and consumers while increasing the efficiency of our operations, which translated into improved profitability with EBITDA up 16.8 percent versus last year. The actions that had the most impact were the optimization of our pricing structure, cost improvements and perfecting our execution at the point of sale; combined, these steps enabled us increase our market share and strengthen our leading position in the various categories and territories in which we participate."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The European Union's executive arm has ordered the Irish government to recover up to 13 billion euros, or $14.5 billion, in taxes from Apple Inc. The European Commission said it has concluded that Ireland granted the U.S. tech giant undue tax benefits of up to 13 billion euros, which is illegal under EU state aid rules. Shares of Apple are down 1 percent in pre-market activity. Abercrombie & Fitch Co. (ANF) reported Tuesday a wider year-over-year net loss for the second-quarter, hurt by a impairment charge. Net sales for the quarter were down 4%, with comparable sales declined 4%. Quarterly loss was wider than their expectations, but revenues beat their' estimates. The performance of Biotech stocks thus far this month is nothing to write home about, if we were to look at it from the standpoint of the movement of the NYSE Arca Biotechnology Index. A peek at what transpired on the FDA front in August and a preview of what September holds in store for us look pertinent.
comments powered by Disqus
Follow RTT